A post-marketing surveillance study of dabrafenib and trametinib combination in Japanese patients with unresectable advanced or recurrent BRAF-mutated NSCLC
Abstract Combination therapy with dabrafenib and trametinib has been shown to improve response and survival outcomes in patients with BRAF V600E-mutated non–small cell lung cancer (NSCLC). However, safety and efficacy data in Japanese patients with unresectable NSCLC are limited in clinical trials....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-07467-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|